Oncology specialists Poniard Pharmaceuticals have successfully enrolled 75 patients in a trial for its new drug treatment for the aggressive small cell lung cancer (SCLC).  The product called Picoplatin is an intravenous platinum-based chemotherapy drug that has been designed to overcome the problems normally associated with resistance in chemotherapy regimes using platinum compounds.  Picoplatin is Poniard’s leading candidate for a treatment for SCLC, which is the most deadly and aggressive form of lung cancer accounting for roughly 20 per cent of all cases presented to US and European doctors.